The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA's Legislative Request on Rx and Compounded Drug Advertising Coalition for Healthcare Communication RFK Jr. & claimed regenerative peptides like BPC 157 The Niche Wave of FDA Warning Letters to Injectable Compounders in Q1 2014 Follows 2013 Inspection Blitz and Legislative Empowerment; Reci The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA to weigh easing limits on unproven peptides